首页> 美国卫生研究院文献>other >SNF5 Reexpression in Malignant Rhabdoid Tumors Regulates Transcription of Target Genes by Recruitment of SWI/SNF Complexes and RNAPII to the Transcription Start Site of Their Promoters
【2h】

SNF5 Reexpression in Malignant Rhabdoid Tumors Regulates Transcription of Target Genes by Recruitment of SWI/SNF Complexes and RNAPII to the Transcription Start Site of Their Promoters

机译:sNF5再表达靶基因的恶性横纹肌样瘤调节转录通过sWI / sNF复合物与RNapII募集到它们的启动子的转录起始位点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Malignant rhabdoid tumor (MRT), a highly aggressive cancer of young children, displays inactivation or loss of the hSNF5/INI1/SMARCB1 gene, a core subunit of the SWI/SNF chromatin-remodeling complex, in primary tumors and cell lines. We have previously reported that reexpression of hSNF5 in some MRT cell lines causes a G1 arrest via p21CIP1/WAF1 (p21) mRNA induction in a p53-independent manner. However, the mechanism(s) by which hSNF5 reexpression activates gene transcription remains unclear. We initially searched for other hSNF5 target genes by asking whether hSNF5 loss altered regulation of other consensus p53 target genes. Our studies show that hSNF5 regulates only a subset of p53 target genes, including p21 and NOXA, in MRT cell lines. We also show that hSNF5 reexpression modulates SWI/SNF complex levels at the transcription start site (TSS) at both loci and leads to activation of transcription initiation through recruitment of RNA polymerase II (RNAPII) accompanied by H3K4 and H3K36 modifications. Furthermore, our results show lower NOXA expression in MRT cell lines compared with other human tumor cell lines, suggesting that hSNF5 loss may alter the expression of this important apoptotic gene. Thus, one mechanism for MRT development after hSNF5 loss may rely on reduced chromatin-remodeling activity of the SWI/SNF complex at the TSS of critical gene promoters. Furthermore, because we observe growth inhibition after NOXA expression in MRT cells, the NOXA pathway may provide a novel target with clinical relevancy for treatment of this aggressive disease.
机译:恶性横纹肌瘤(MRT)是一种高度侵袭性的年幼儿童癌症,在原发性肿瘤和细胞系中显示出hSNF5 / INI1 / SMARCB1基因(SWI / SNF染色质重塑复合体的核心亚基)的失活或缺失。我们以前曾报道过,在某些MRT细胞系中hSNF5的重新表达通过p21 CIP1 / WAF1 (p21)mRNA诱导以p53独立的方式引起G1阻滞。然而,hSNF5重新表达激活基因转录的机制仍不清楚。我们最初通过询问hSNF5丢失是否改变了其他共有p53靶基因的调节来搜索其他hSNF5靶基因。我们的研究表明,hSNF5仅调节MRT细胞系中p53靶基因的一个子集,包括p21和NOXA。我们还显示,hSNF5重新表达可在两个基因座的转录起始位点(TSS)上调节SWI / SNF复合物水平,并通过伴随H3K4和H3K36修饰的RNA聚合酶II(RNAPII)募集导致转录起始的激活。此外,我们的研究结果显示,与其他人类肿瘤细胞系相比,MRT细胞系中NOXA的表达较低,这表明hSNF5的缺失可能会改变这一重要凋亡基因的表达。因此,hSNF5丢失后MRT发展的一种机制可能取决于SWI / SNF复合体在关键基因启动子的TSS上降低的染色质重塑活性。此外,因为我们观察到MRT细胞中NOXA表达后的生长抑制,所以NOXA途径可能为治疗这种侵袭性疾病提供了具有临床意义的新靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号